Oak Associates Ltd. OH boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 2.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,675 shares of the biotechnology company’s stock after buying an additional 105 shares during the period. Oak Associates Ltd. OH’s holdings in United Therapeutics were worth $549,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc raised its stake in United Therapeutics by 1.7% during the 3rd quarter. Vanguard Group Inc now owns 3,775,103 shares of the biotechnology company’s stock valued at $482,760,000 after acquiring an additional 61,361 shares during the last quarter. BB&T Corp raised its stake in shares of United Therapeutics by 2.3% during the 4th quarter. BB&T Corp now owns 10,996 shares of the biotechnology company’s stock worth $1,197,000 after buying an additional 246 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of United Therapeutics by 46.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 26,978 shares of the biotechnology company’s stock worth $2,938,000 after buying an additional 8,542 shares in the last quarter. IFM Investors Pty Ltd raised its stake in shares of United Therapeutics by 12.2% during the 4th quarter. IFM Investors Pty Ltd now owns 2,644 shares of the biotechnology company’s stock worth $288,000 after buying an additional 288 shares in the last quarter. Finally, Arizona State Retirement System raised its stake in shares of United Therapeutics by 1.1% during the 4th quarter. Arizona State Retirement System now owns 31,284 shares of the biotechnology company’s stock worth $3,407,000 after buying an additional 352 shares in the last quarter. Institutional investors and hedge funds own 96.47% of the company’s stock.
In other United Therapeutics news, Director Christopher Patusky sold 3,370 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $110.75, for a total transaction of $373,227.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 8.20% of the stock is currently owned by corporate insiders.
United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) EPS for the quarter, missing analysts’ consensus estimates of $2.64 by ($13.96). The company had revenue of $362.70 million for the quarter, compared to analyst estimates of $335.72 million. United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. United Therapeutics’s quarterly revenue was down 6.8% compared to the same quarter last year. During the same quarter last year, the company posted $3.76 EPS. As a group, equities research analysts predict that United Therapeutics Co. will post -5.03 earnings per share for the current fiscal year.
Several equities analysts recently weighed in on the company. Wedbush raised their price objective on United Therapeutics from $269.00 to $273.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Credit Suisse Group raised United Therapeutics from an “underperform” rating to a “neutral” rating and set a $98.00 price objective for the company in a research note on Thursday, May 9th. BidaskClub downgraded United Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, April 19th. ValuEngine downgraded United Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, April 18th. Finally, Cowen reaffirmed a “hold” rating and issued a $103.00 price objective on shares of United Therapeutics in a research note on Wednesday, May 1st. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. United Therapeutics has a consensus rating of “Hold” and an average target price of $129.00.
COPYRIGHT VIOLATION WARNING: “United Therapeutics Co. (UTHR) Shares Bought by Oak Associates Ltd. OH” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/4354188/united-therapeutics-co-uthr-shares-bought-by-oak-associates-ltd-oh.html.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Further Reading: Google Finance Portfolio
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.